



Prevalence of Plasmid-Mediated Quinolone Resistance Genes Among *Escherichia coli* in the Gut of Healthy People in Fuzhou, China

Bin Li, Ph.D.^{1,*}, Yao Chen, M.D.^{1,*}, Zhiyun Wu, M.D.¹, Zhichang Zhao, M.D.², Juan Wu, M.D.¹, and Yingping Cao, Ph.D.¹

Departments of Clinical Laboratory¹ and Pharmacy², Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Dear Editor,

The intestinal tract may be an important reservoir for antibiotic-resistant genes [1]. Determining the prevalence of quinolone resistance in intestinal bacteria within the community is important for both healthy subjects and hospital patients as quinolone is one of the most commonly used antibiotics in China. The prevalence of plasmid-mediated quinolone resistance (PMQR) gene-harboring *Enterobacteriaceae* in the gut flora among healthy humans was previously unknown, so we assessed the prevalence of PMQR genes among commensal *Escherichia coli* in healthy persons from one region in China. This study was approved by the Ethics Committee of the Fujian Medical University Union Hospital (No. 2012KY085). Written informed consent was obtained from all participants.

From July to October 2013, fecal samples were collected at a teaching hospital in Fuzhou (China) from healthy subjects at their annual physical examination. None of the subjects had been exposed to antibiotics or a hospital environment in the three months prior to sample collection. A total of 429 fecal samples, one per person, were examined. Samples were screened using MacConkey agar plates supplemented with levofloxacin (0.125 µg/mL). Among the 429 participants, 220 (51.3%) were males and 209 (48.7%) were females. The age range was 6–84 years

(median age: 48 years). Four participants were under 18 years old, and the rest were over 18 years.

In this study, 89.0% (382/429) of the samples were colonized with *E. coli* with reduced quinolone susceptibility. Previous research on community carriage of quinolone-resistant *Enterobacteriaceae* described carriage rates that were highly different from our findings [2, 3], probably because of factors such as regional differences in climate, eating patterns, and sanitary conditions.

PMQR determinants were screened by PCR in 382 levofloxacin-resistant *E. coli* fecal isolates as previously described [4]. The results showed that 31.4% (120/382) of fecal *E. coli* harbored PMQR determinants. Among 120 PMQR-positive isolates, *qnr* genes were the most common determinants (41.7%), followed by *aac (6′)-Ib-cr* (36.7%) and *oqxAB* (35.8%) (Table 1). Among 50 *qnr*-positive *E. coli*, *qnrS1* was the most common PMQR gene (94.0%), as reported by previous studies [3, 4]. *qnrB1* was detected in four isolates (Table 1); *qnrA*, *qnrC*, and *qnrD* were not found. Usually, *aac (6′)-Ib-cr* is more common than *qnr* genes [5]. A previous study showed that strain selection criteria may underestimate the presence of bacteria harboring *aac (6′)-Ib-cr* [6], which probably explains the low prevalence of this PMQR determinant in our study.

Received: August 4, 2017

Revision received: September 18, 2017

Accepted: March 12, 2018

Corresponding author: Yingping Cao

Department of Clinical Laboratory, Fujian Medical University Union Hospital, 29 Xinquan Rd., Fuzhou, Fujian, 350001, China
Tel: +86-591-86218678, E-mail: caoyingping918@hotmail.com

*These authors contributed equally to this study.

© Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. Distribution of PMQR genes in *E. coli* phylogenetic groups and the corresponding fluoroquinolone minimal inhibitory concentration (MIC) ranges

PMQR genes	N	Phylogenetic group (N, %)				Ciprofloxacin (µg/mL)			Levofloxacin (µg/mL)		
		A	B ₁	B ₂	D	MIC range	MIC ₅₀	MIC ₉₀	MIC range	MIC ₅₀	MIC ₉₀
<i>qnrS1</i>	38	25 (65.8)	9 (23.7)	4 (10.5)	0	1–64	4	32	1–128	4	32
<i>aac(6')Ib-cr</i>	33	16 (48.5)	6 (18.2)	3 (9.1)	8 (24.2)	1–256	32	128	2–64	8	32
<i>oqxA+oqxB</i>	32	18 (56.3)	10 (31.3)	0	4 (12.5)	1–64	8	32	1–32	8	16
<i>qnrS1+oqxA+oqxB</i>	6	3 (50)	3 (50)	0	0	1–8	2	8	1–32	4	32
<i>aac(6')Ib-cr+oqxA+oqxB</i>	4	2 (50)	2 (50)	0	0	8–32	16	32	16–32	16	32
<i>qnrS1+ aac(6')Ib-cr</i>	2	2 (100)	0	0	0	-	-	-	-	-	-
<i>qnrB1+aac(6')Ib-cr</i>	2	2 (100)	0	0	0	-	-	-	-	-	-
<i>oqxA</i>	1	0	0	0	1	-	-	-	-	-	-
<i>qnrS1+qnrB1+aac(6')Ib-cr</i>	1	1	0	0	0	-	-	-	-	-	-
<i>qnrB1+aac(6')Ib-cr+oqxA+oqxB</i>	1	1	0	0	0	-	-	-	-	-	-
Total	120	70 (58.3)	30 (25.0)	7 (5.8)	13 (16.7)						

Abbreviations: MIC₅₀, minimum inhibitory concentration required to kill 50% of the microbial population; MIC₉₀, minimum inhibitory concentration required to kill 90% of the microbial population.

Table 2. Association between antimicrobial susceptibility and β-lactamase genes in PMQR-positive *E. coli* isolates

Antimicrobial agents	MIC (µg/mL)			Resistance rate (%)						P*
				Total (N=120)		β-lactamase gene-positive strains (N=99)		β-lactamase gene-negative strains (N=21)		
	MIC range	MIC ₅₀	MIC ₉₀	S	R	S	R	S	R	
Nalidixic acid	16–512	512	512	0	100	0	100	0	100	-
Ciprofloxacin	0.5–512	8	64	9.2	78.3	8.1	81.8	14.3	57.1	0.407
Levofloxacin	0.5–256	8	32	10.8	66.7	10.1	71.7	14.3	42.9	0.463
Cefotaxime	0.125–512	0.125	128	56.7	43.3	51.5	48.5	85.7	14.3	0.004
Gentamicin	0.125–512	2	128	52.5	45.8	49.5	48.5	71.4	28.6	0.081
Cefepime	0.125–512	0.125	8	92.5	4.2	92.9	3.0	95.2	4.8	0.555
Amikacin	0.125–512	2	2	97.5	2.5	97.0	3.0	100	0	1.000
Imipenem	0.125–4	0.25	0.5	100	0	100	0	100	0	-

*Statistical significance (P) was calculated using the Pearson Chi-square test in terms of the number of resistant strains and susceptible strains in the β-lactamase gene-positive and β-lactamase gene-negative groups. Intermediate isolates were considered non-susceptible isolates.

Abbreviations: S, susceptible; R, resistant; MIC, minimum inhibitory concentration; MIC₅₀, minimum inhibitory concentration required to kill 50% of the microbial population; MIC₉₀, minimum inhibitory concentration required to kill 90% of the microbial population.

PMQR determinants are frequently associated with extended spectrum beta-lactamase (ESBL) in *Enterobacteriaceae* [5]. In this study, β-lactamase genes (*bla*TEM, *bla*SHV, and *bla*CTX-M) were detected as described previously [7]. Ninety-nine (82.5%) strains co-harbored β-lactamase genes. *bla*TEM-1, *bla*CTX-M-1 group, and *bla*CTX-M-9 group were found in 72 (72.3%), 24 (24.2%), and 21 (21.2%) isolates, respectively. Overall, *bla*CTX-M-15 was the predominant ESBL genotype (20.2%, 20/99), followed by *bla*CTX-M-14 (13.1%, 13/99), *bla*CTX-M-65 (5.1%, 5/99), *bla*CTX-M-79 (4.0%, 4/99), *bla*CTX-M-27 (2.0%, 2/99), and *bla*CTX-M-98 (1.0%, 1/99). *bla*SHV, *bla*CTX-

M-2 group, and *bla*CTX-M-8 group were not found. Different PMQR genes tend to co-exist with specific cephalosporin resistance genes. For example, *qnrA* and *qnrB* are usually found with *bla*CTX-M and *bla*SHV, and *qnrS* is always located on plasmids carrying *bla*TEM-1 [8]. These might explain why in our study, most PMQR-positive isolates produced *bla*TEM-1 and less than half of the strains co-harbored *bla*CTX-M.

PMQR-harboring fecal *E. coli* were tested for susceptibility toward nine different antimicrobials according to the CLSI [9]. These isolates showed high resistance against nalidixic acid (100%,

120/120), ciprofloxacin (78.3%, 94/120), and levofloxacin (66.7%, 80/120). Resistance rates to gentamicin, cefotaxime, cefepime, and amikacin were less than 50% (Table 2). All strains were susceptible to imipenem. Antibiotic susceptibilities of β -lactamase gene-positive and β -lactamase gene-negative PMQR-positive *E. coli* are shown in Table 2. A higher percentage of resistance to cefotaxime was observed in β -lactamase gene-positive isolates than in negative isolates (Table 2).

Molecular characteristics of PMQR-positive *E. coli* fecal isolates were determined, including phylogenetic grouping and random amplified polymorphic DNA analysis as previously described [2, 7]. The distribution of PMQR genes in *E. coli* phylogenetic groups is shown in Table 1. PMQR-positive *E. coli* fecal strains (120) were categorized into 71 genotypes; three strains were non-typeable, suggesting a non-clonal origin.

In conclusion, our study demonstrated a high prevalence of quinolone-resistant *E. coli* colonization in the gut flora of healthy subjects in one region of China. PMQR determinants were widely disseminated among those strains. Rational antibiotic use is imperative, and intervention programs and policies are urgently needed to control the colonization and dissemination of quinolone-resistant *Enterobacteriaceae* to promote public health in China.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgment

This study was supported by the National Natural Science Foundation of China (grant no. 81201328), and the Medical Elite Cultivation Program of Fujian, China (grant no. 2015-ZQN-ZD-15).

REFERENCES

1. Huddleston JR. Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes. *Infect Drug Resist* 2014;7:167-76.
2. Gao L, Hu J, Zhang X, Wei L, Li S, Miao Z, et al. Application of swine manure on agricultural fields contributes to extended-spectrum β -lactamase-producing *Escherichia coli* spread in Tai'an, China. *Front Microbiol* 2015; 6:313.
3. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant *Escherichia coli* in the community. *Antimicrob Agents Chemother* 1999;43: 2736-41.
4. Li B, Sun JY, Liu QZ, Han LZ, Huang XH, Ni YX. High prevalence of CTX-M β -lactamases in faecal *Escherichia coli* strains from healthy humans in Fuzhou, China. *Scand J Infect Dis* 2011;43:170-4.
5. Le TM, Baker S, Le TP, Le TP, Cao TT, Tran TT, et al. High prevalence of plasmid-mediated quinolone resistance determinants in commensal members of the *Enterobacteriaceae* in Ho Chi Minh City, Vietnam. *J Med Microbiol* 2009; 58:1585-92.
6. Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. *Microbiol Spectr* 2014;2, doi: 10.1128/microbiolspec.PLAS-0006-2013.
7. Musumeci R, Rausa M, Giovannoni R, Cialdella A, Bramati S, Sibra B, et al. Prevalence of plasmid-mediated quinolone resistance genes in uropathogenic *Escherichia coli* isolated in a teaching hospital of northern Italy. *Microb Drug Resist* 2012;18:33-41.
8. Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: an update. *J Infect Chemother* 2011;17:149-82.
9. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 24th ed. CLSI supplement M100-S26. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.